Sarepta Therapeutics, Inc. (SRPT) shares collapsed 45.30 percent, or $16.40, to $19.78 on Monday after reports of a possible death of a recipient in the company's second gene therapy clinical trial stated by Investor's Business Daily. The news has sparked significant investor concern over the safety profile of the treatment. The stock opened at $21.26 and has fluctuated between $18.30 and $21.55 during the session on the Nasdaq. Volume has spiked to 25.96 million shares, sharply higher than the average of 3.90 million. The 52-week range for the stock is $18.30 to $173.25.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.